{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:36:20Z","timestamp":1779291380140,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for Innovative New Diagnostics"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean Ministry of Health, Welfare and Family"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mutations in the genes inhA, katG, and rpoB confer resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin. We questioned whether specific mutations in these genes were associated with different clinical and microbiological characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rpoB mutations in sputum isolates using the Hain MTBDRplus line probe assay. For specific mutations, we performed bivariate analysis to determine relative risk of baseline or acquired resistance to other TB drugs. We compared time to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 447 participants enrolled from January 2005 to December 2008 from 7 countries were included. Relative to rpoB S531L, isolates with rpoB D516V had less cross-resistance to rifabutin, increased baseline resistance to other drugs, and increased acquired fluoroquinolone resistance. Relative to mutation of katG only, mutation of inhA promoter and katG was associated with baseline extensively drug resistant (XDR) TB, increased acquired fluoroquinolone resistance, and slower TSCC (125.5 vs 89.0 days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Specific mutations in inhA and katG are associated with differences in resistance to other drugs and TSCC. Molecular testing may make it possible to tailor treatment and assess additional drug resistance risk according to specific mutation profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa042","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T20:49:03Z","timestamp":1580244543000},"page":"2072-2082","source":"Crossref","is-referenced-by-count":19,"title":["Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion"],"prefix":"10.1093","volume":"221","author":[{"given":"Eleanor S","family":"Click","sequence":"first","affiliation":[{"name":"Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina V","family":"Kurbatova","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Alexander","sequence":"first","affiliation":[{"name":"Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy L","family":"Dalton","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E","family":"Posey","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ershova","sequence":"first","affiliation":[{"name":"Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Peter","family":"Cegielski","sequence":"first","affiliation":[{"name":"Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"2020061115544875500_CIT0001","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2017"},{"key":"2020061115544875500_CIT0002","doi-asserted-by":"crossref","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2020061115544875500_CIT0003","doi-asserted-by":"crossref","first-page":"e1007297","DOI":"10.1371\/journal.ppat.1007297","article-title":"Pathogen-based precision medicine for drug-resistant tuberculosis","volume":"14","author":"Gr\u00f6schel","year":"2018","journal-title":"PLoS Pathog"},{"key":"2020061115544875500_CIT0004","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/JCM.00521-07","article-title":"Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens","volume":"45","author":"Hillemann","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2020061115544875500_CIT0005","doi-asserted-by":"crossref","first-page":"MGM2-0014-2013","DOI":"10.1128\/microbiolspec.MGM2-0014-2013","article-title":"Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities","volume":"2","author":"Vilcheze","year":"2014","journal-title":"Microbiol Spectr"},{"key":"2020061115544875500_CIT0006","doi-asserted-by":"crossref","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"key":"2020061115544875500_CIT0007","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/AAC.43.8.1866","article-title":"Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis","volume":"43","author":"Billington","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115544875500_CIT0008","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/AAC.48.4.1289-1294.2004","article-title":"Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis","volume":"48","author":"Mariam","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115544875500_CIT0009","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1124410","article-title":"The competitive cost of antibiotic resistance in Mycobacterium tuberculosis","volume":"312","author":"Gagneux","year":"2006","journal-title":"Science"},{"key":"2020061115544875500_CIT0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tig.2012.11.005","article-title":"The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis","volume":"29","author":"M\u00fcller","year":"2013","journal-title":"Trends Genet"},{"key":"2020061115544875500_CIT0011","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1128\/AAC.06460-11","article-title":"Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis","volume":"56","author":"Fenner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115544875500_CIT0012","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(12)60734-X","article-title":"Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study","volume":"380","author":"Dalton","year":"2012","journal-title":"Lancet"},{"key":"2020061115544875500_CIT0013","doi-asserted-by":"crossref","first-page":"e1001932","DOI":"10.1371\/journal.pmed.1001932","article-title":"Association between regimen composition and treatment response in patients with multidrug-resistant tuberculosis: a prospective cohort study","volume":"12","author":"Yuen","year":"2015","journal-title":"PLoS Med"},{"key":"2020061115544875500_CIT0014","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"2020061115544875500_CIT0015","doi-asserted-by":"crossref","first-page":"e1538","DOI":"10.1371\/journal.pone.0001538","article-title":"Evolution and diversity of clonal bacteria: the paradigm of Mycobacterium tuberculosis","volume":"3","author":"Dos Vultos","year":"2008","journal-title":"PLoS One"},{"key":"2020061115544875500_CIT0016","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fmicb.2016.01947","article-title":"Correlation of rpoB mutations with minimal inhibitory concentration of rifampin and rifabutin in Mycobacterium tuberculosis in an HIV\/AIDS endemic setting, South Africa","volume":"7","author":"Rukasha","year":"2016","journal-title":"Front Microbiol"},{"key":"2020061115544875500_CIT0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2016.01.019","article-title":"Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex","volume":"85","author":"Berrada","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020061115544875500_CIT0018","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10156-010-0057-5","article-title":"Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay","volume":"16","author":"Yoshida","year":"2010","journal-title":"J Infect Chemother"},{"key":"2020061115544875500_CIT0019","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JCM.00691-14","article-title":"Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis","volume":"52","author":"Jamieson","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020061115544875500_CIT0020","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.5588\/ijtld.14.0936","article-title":"Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations","volume":"19","author":"ElMaraachli","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020061115544875500_CIT0021","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2020061115544875500_CIT0022","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/mmi.13606","article-title":"Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis","volume":"103","author":"Molodtsov","year":"2017","journal-title":"Mol Microbiol"},{"key":"2020061115544875500_CIT0023","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/mmi.12476","article-title":"A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis","volume":"91","author":"Ando","year":"2014","journal-title":"Mol Microbiol"},{"key":"2020061115544875500_CIT0024","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","article-title":"Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations","volume":"8","author":"Lempens","year":"2018","journal-title":"Sci Rep"},{"key":"2020061115544875500_CIT0025","doi-asserted-by":"crossref","first-page":"946","DOI":"10.5588\/ijtld.13.0926","article-title":"Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment","volume":"18","author":"Abate","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020061115544875500_CIT0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2334-12-9","article-title":"Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India","volume":"12","author":"Tolani","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2020061115544875500_CIT0027","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00077-13","article-title":"Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes","volume":"57","author":"Huyen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115544875500_CIT0028","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1128\/JCM.02505-15","article-title":"MTBDRplus and MTBDRsl assays: absence of wild-type probe hybridization and implications for detection of drug-resistant tuberculosis","volume":"54","author":"Seifert","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2020061115544875500_CIT0029","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa1800474","article-title":"Prediction of susceptibility to first-line tuberculosis drugs by DNA Sequencing","volume":"379","author":"The CRyPTIC Consortium and the 100,000 Genomes Project","year":"2018","journal-title":"N Engl J Med"},{"key":"2020061115544875500_CIT0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5588\/ijtld.17.0715","article-title":"Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?","volume":"22","author":"Bouzouita","year":"2018","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa042\/33015284\/jiaa042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/12\/2072\/33379731\/jiaa042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/12\/2072\/33379731\/jiaa042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:10:03Z","timestamp":1591909803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/12\/2072\/5718252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,1,31]]},"published-print":{"date-parts":[[2020,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa042","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,15]]},"published":{"date-parts":[[2020,1,31]]}}}